Get started
Author

Jonathan Pak

Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes
2023 · Neha J. Pagidipati, Adam J. Nelson, et al. · JAMA · 108
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
2021 · Adam J. Nelson, Neha J. Pagidipati, et al. · Circulation · 79
Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
2022 · Adam J. Nelson, Emily C. O’Brien, et al. · JAMA Network Open · 78
PDF
Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022
2022 · Diya Surie, Levi Bonnell, et al. · MMWR Morbidity and Mortality Weekly Report · 59
PDF
The First Year Experience with the Dual Chamber ICD
2000 · STEVEN L. HIGGINS, JONATHAN P. PAK, et al. · Pacing and Clinical Electrophysiology · 15
Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) – Diabetes: rationale and design
2022 · Adam J. Nelson, Neha J. Pagidipati, et al. · American Heart Journal · 11
The Association Between Type 2 Diabetes and Cardiovascular Disease: The “For Your SweetHeart™” Survey
2019 · Leigh Perreault, Marilyn K. Boardman, et al. · Advances in Therapy · 11
PDF
Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial
2024 · Manasi Tannu, Lisa Kaltenbach, et al. · Circulation · 9
PDF
Primary Care Physicians’ Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey
2020 · Jay H. Shubrook, Jonathan Pak, et al. · Advances in Therapy · 9
PDF
Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics
2024 · Adam J. Nelson, Lisa A. Kaltenbach, et al. · American Heart Journal · 8
Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings
2024 · Aaron S. Kelly, Melanie Bahlke, et al. · Pediatric Obesity · 5
PDF
Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey
2020 · Nathan D Wong, Wenjun Fan, et al. · Diabetes and Vascular Disease Research · 3
PDF
Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-diabetes trial
2025 · Adam J Nelson, Lisa A. Kaltenbach, et al. · American Journal of Preventive Cardiology · 1
Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes
2025 · Shubham Agarwal, Mujeeb A. Basit, et al. · Frontiers in Cardiovascular Medicine · 1
PDF
Intervention to Improve Guideline-based Care for Diabetes and Cardiovascular Disease Is Effective in Black and Hispanic Populations
2024 · Jennifer Green, Adam J. Nelson, et al. · Journal of the American College of Cardiology · 1
US Healthcare Professionals’ Management of MASH and Knowledge of GLP-1, GIP, and Glucagon Receptor Agonists
2026 · Harold E. Bays, Jonathan Pak, et al. · Clinical and Translational Gastroenterology
770-P: Persistence of Prescription Gaps of SGLT2i and GLP-1RA in Type 2 Diabetes and Cardiorenal Disease—A Current Global Perspective
2025 · SHUBHAM AGARWAL, YASER A. ELNAKIEB, et al. · Diabetes
Characteristics of Persons With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Prescribed Sglt-2i And/or Glp-1ra Among Cardiology Clinics in the Us: Insights From a Large Implementation Trial
2024 · Adam J. Nelson, Neha J. Pagidipati, et al. · Journal of the American College of Cardiology
Persistence and Discontinuation of Sglt-2i and Glp-1ra Among Persons With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Treated in Us Cardiology Clinics: Insights From the Coordinate-diabetes Trial
2024 · Adam J. Nelson, Neha J. Pagidipati, et al. · Journal of the American College of Cardiology
1066-P: Gaps in Guideline-Indicated Prescribing of GLP1RA/SGLT2i in Patients with T2DM and Cardiorenal Disease according to ADA Standards of Care
2023 · ILDIKO LINGVAY, MICHAEL E. BOWEN, et al. · Diabetes
Abstract 9041: Provider Evaluation for Selection of Evidence-Based Therapies to Reduce Cardiovascular Complications in Patients With Type 2 Diabetes Mellitus Study - Primary Results of the PREFER-DM Study
2021 · Abhinav Sharma, Marat Fudim, et al. · Circulation
Abstract 10159: Underuse of Evidence-based Therapies for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease: Insights from Clinical Research Networks in the United States
2021 · Adam J Nelson, Emily O'Brien, et al. · Circulation
2226-PUB: A Survey of Primary Care Physicians (PCPs): Knowledge of Cardiovascular Outcomes Trials and Treatment Implications
2019 · GEORGE E. DAILEY, JONATHAN PAK, et al. · Diabetes
Empa-reg Outcome Eligibility and Preventable Cardiovascular Events in the Us Population: an Analysis of the National Health and Nutrition Examination Survey
2019 · Nathan D. Wong, Wenjun Fan, et al. · Journal of the American College of Cardiology
PDF
The Association Between Type 2 Diabetes and Cardiovascular Disease: The “For Your SweetHeart™” Survey
2019 · Perreault, Leigh, Boardman, Marilyn K., et al. · Figshare
Works count: 27
Citation count: 398
H-index: 9
I10-index: 7
Year
Topic
Type